Effect of Recombinant Human Brain Natriuretic Peptide and Levosimendan for Injection in the Treatment of Heart Failure Caused by Ischemic Cardiomyopathy
Objective To observe the effects of recombinant human brain natriuretic peptide and levosimendan on pulmonary capillary wedge pressure(PCWP),pulmonary arterial pressure(PAP)levels,and myocardial cell function in patients with ischemic cardiomyopathy induced heart failure.Methods A total of 160 patients with heart failure caused by ischemic cardiomyopathy who were admitted to the hospital from April 2021 to April 2023 were selected,and the random method was used,and the group results were that the patients entered the combination group and the control group with 80 cases,respectively.The control group received basic treatment such as levosimendan,and the combined group received combined treatment of recombinant human brain natriuretic peptide on the basis of the control group.The efficacy,hemodynamic parameters,myocardial cell function and cardiac function were compared between the groups.The incidence of adverse reactions was calculated.Results After treatment,The total effective rate of the combination group was 93.75％,which was higher than that of the control group(P＜0.05).The PCWP,PAP and N-terminal pro-brain natriuretic peptide(NT-proBNP)levels in the two groups were reduced,and these indicators in the combination group were lower than those in the control group(P＜0.05).The left ventricular ejection fraction(LVEF)of the two groups was higher than that before treatment,and the left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)levels were lower than that before treatment,while the LVEF level in the combined group was relatively higher,while the level of LVESD and LVEDD was relatively lower(P＜0.05).The incidence of adverse reactions in the combination group was 10.00％within one month after treatment,which was not statistically significant compared with the total incidence of adverse reactions in the control group(P＞0.05).Conclusion Lyophilized recombinant human brain natriuretic peptide combined with levosimendan can help regulate PCWP,PAP and myocardial cell function in patients with heart failure caused by ischemic cardiomyopathy,and improve cardiac function,without increasing the risk of adverse drug reactions.
ischemic cardiomyopathyheart failurelevosimendanlyophilized recombinant human brain natriuretic peptidepulmonary capillary wedge pressurepulmonary arterial pressuremyocardial cell function
万方数据
维普
